Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Kidney Cancer | Research

Potential prognostic and therapeutic value of ANXA8 in renal cell carcinoma: based on the comprehensive analysis of annexins family

Authors: Li-Hui Wang, Bo Cao, Yun-Long Li, Bao-Ping Qiao

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Annexins are a family of proteins involved in a wide variety of cellular processes such as inflammation, proliferation, differentiation, apoptosis, migration and membrane repair. However, the role of most Annexins in renal cell carcinoma (RCC) remained unclear.

Methods

The differentially expressed Annexins in RCC compared with normal controls were screened applying the TCGA database. The correlation of differentially expressed Annexins with clinical stages, grades and overall survival was analyzed to explore the clinical significance of Annexins in RCC. Then ANXA8 was selected and further stained in the discover and validation RCC cohort. The correlation of ANXA8 expression with clinical parameter was verified at the protein level. To explore the potential function of ANXA8, ANXA8 was knockdown in the RCC cell line and further analyzed using transcriptome and bioinformatic analysis.

Results

mRNA expression of ANXA1, ANXA2R, ANXA4, ANXA8, ANXA8L1 and ANXA13 were significantly upregulated in RCC compared with normal kidney tissues. In contrast, ANXA3 and ANXA9 mRNA expression was significantly downregulated. Higher expression of ANXA2R, ANXA8 and ANXA8L1 were correlated with worse overall survival, while lower expression of ANXA3, ANXA9 and ANXA13 were associated with worse clinical outcomes in RCC patients. We further demonstrated that ANXA8 expression was significantly increased in RCC compared with normal renal tissues at the protein level. And higher protein expression of ANXA8 was associated with higher clinical grades. Through the bioinformatics analysis and cell cycle analysis, we found knockdown of ANXA8 mainly influenced the cell cycle and DNA replication. The top ten hub genes consist of CDC6, CDK2, CHEK1, CCNB1, ORC1, CHEK2, MCM7, CDK1, PCNA and MCM3.

Conclusions

Multiple members of Annexins were abnormally expressed and associated with the prognosis of RCC. The expression of ANXA8 was significantly increased in RCC and associated with poor prognosis. ANXA8 might influence the cell cycle and could be a potential biomarker and therapeutic target for RCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014;64:9–29.CrossRef Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014;64:9–29.CrossRef
2.
go back to reference Kim MC, Jin Z, Kolb R, Borcherding N, Chatzkel JA, Falzarano SM et al. Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers. 2021;13. Kim MC, Jin Z, Kolb R, Borcherding N, Chatzkel JA, Falzarano SM et al. Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers. 2021;13.
3.
go back to reference Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2 + signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6:449–61.CrossRefPubMed Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2 + signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6:449–61.CrossRefPubMed
4.
go back to reference Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol. 2008;216:131–40.CrossRefPubMed Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol. 2008;216:131–40.CrossRefPubMed
5.
6.
go back to reference Yang L, Lu P, Yang X, Li K, Qu S. Annexin A3, a calcium-dependent phospholipid-binding protein: implication in Cancer. Front Mol Biosci. 2021;8:716415.CrossRefPubMedPubMedCentral Yang L, Lu P, Yang X, Li K, Qu S. Annexin A3, a calcium-dependent phospholipid-binding protein: implication in Cancer. Front Mol Biosci. 2021;8:716415.CrossRefPubMedPubMedCentral
7.
go back to reference Yamanoi M, Yamanoi K, Fujii C, Fukuda MN, Nakayama J. Annexin A1 expression is correlated with malignant potential of renal cell carcinoma. Int J urology: official J Japanese Urol Association. 2019;26:284–90.CrossRef Yamanoi M, Yamanoi K, Fujii C, Fukuda MN, Nakayama J. Annexin A1 expression is correlated with malignant potential of renal cell carcinoma. Int J urology: official J Japanese Urol Association. 2019;26:284–90.CrossRef
8.
go back to reference Yang SF, Hsu HL, Chao TK, Hsiao CJ, Lin YF, Cheng CW. Annexin A2 in renal cell carcinoma: expression, function, and prognostic significance. Urol Oncol. 2015;33:22e11–22e1.CrossRef Yang SF, Hsu HL, Chao TK, Hsiao CJ, Lin YF, Cheng CW. Annexin A2 in renal cell carcinoma: expression, function, and prognostic significance. Urol Oncol. 2015;33:22e11–22e1.CrossRef
9.
go back to reference Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, Tachibana M. Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer. 2009;101:287–94.CrossRefPubMedPubMedCentral Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, Tachibana M. Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer. 2009;101:287–94.CrossRefPubMedPubMedCentral
10.
go back to reference Zimmermann U, Woenckhaus C, Pietschmann S, Junker H, Maile S, Schultz K, et al. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Archiv: an international journal of pathology. 2004;445:368–74.CrossRefPubMed Zimmermann U, Woenckhaus C, Pietschmann S, Junker H, Maile S, Schultz K, et al. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Archiv: an international journal of pathology. 2004;445:368–74.CrossRefPubMed
11.
go back to reference Tang J, Qin Z, Han P, Wang W, Yang C, Xu Z, et al. High annexin A5 expression promotes tumor progression and poor prognosis in renal cell carcinoma. Int J Oncol. 2017;50:1839–47.CrossRefPubMed Tang J, Qin Z, Han P, Wang W, Yang C, Xu Z, et al. High annexin A5 expression promotes tumor progression and poor prognosis in renal cell carcinoma. Int J Oncol. 2017;50:1839–47.CrossRefPubMed
12.
go back to reference Bianchi C, Bombelli S, Raimondo F, Torsello B, Angeloni V, Ferrero S, et al. Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of annexin A3. Am J Pathol. 2010;176:1660–70.CrossRefPubMedPubMedCentral Bianchi C, Bombelli S, Raimondo F, Torsello B, Angeloni V, Ferrero S, et al. Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of annexin A3. Am J Pathol. 2010;176:1660–70.CrossRefPubMedPubMedCentral
13.
go back to reference Zimmermann U, Balabanov S, Giebel J, Teller S, Junker H, Schmoll D, et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 2004;209:111–8.CrossRefPubMed Zimmermann U, Balabanov S, Giebel J, Teller S, Junker H, Schmoll D, et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 2004;209:111–8.CrossRefPubMed
14.
go back to reference Lee MJ, Yu GR, Yoo HJ, Kim JH, Yoon BI, Choi YK, et al. ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma. Gastroenterology. 2009;137:1138–50. 50.e1-9.CrossRefPubMed Lee MJ, Yu GR, Yoo HJ, Kim JH, Yoon BI, Choi YK, et al. ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma. Gastroenterology. 2009;137:1138–50. 50.e1-9.CrossRefPubMed
15.
go back to reference Stein T, Price KN, Morris JS, Heath VJ, Ferrier RK, Bell AK, et al. Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. Clin cancer research: official J Am Association Cancer Res. 2005;11:6872–9.CrossRef Stein T, Price KN, Morris JS, Heath VJ, Ferrier RK, Bell AK, et al. Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. Clin cancer research: official J Am Association Cancer Res. 2005;11:6872–9.CrossRef
16.
go back to reference Pimiento JM, Chen DT, Centeno BA, Davis-Yadley AH, Husain K, Fulp WJ, et al. Annexin A8 is a prognostic marker and potential therapeutic target for pancreatic Cancer. Pancreas. 2015;44:122–7.CrossRefPubMedPubMedCentral Pimiento JM, Chen DT, Centeno BA, Davis-Yadley AH, Husain K, Fulp WJ, et al. Annexin A8 is a prognostic marker and potential therapeutic target for pancreatic Cancer. Pancreas. 2015;44:122–7.CrossRefPubMedPubMedCentral
17.
go back to reference Yuan JB, Gu L, Chen L, Yin Y, Fan BY. Annexin A8 regulated by lncRNA-TUG1/miR-140-3p axis promotes bladder cancer progression and metastasis. Mol therapy oncolytics. 2021;22:36–51.CrossRef Yuan JB, Gu L, Chen L, Yin Y, Fan BY. Annexin A8 regulated by lncRNA-TUG1/miR-140-3p axis promotes bladder cancer progression and metastasis. Mol therapy oncolytics. 2021;22:36–51.CrossRef
18.
go back to reference Gou R, Zhu L, Zheng M, Guo Q, Hu Y, Li X, et al. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of annexins. J translational Med. 2019;17:275.CrossRef Gou R, Zhu L, Zheng M, Guo Q, Hu Y, Li X, et al. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of annexins. J translational Med. 2019;17:275.CrossRef
20.
21.
go back to reference Zhao JY, Chang LC, Tu JP, Sun B, Wei X. Evaluation of Annexins Family as Potential Biomarker for Predicting Progression and Prognosis in Clear Renal Cell Carcinoma. Preprint. Zhao JY, Chang LC, Tu JP, Sun B, Wei X. Evaluation of Annexins Family as Potential Biomarker for Predicting Progression and Prognosis in Clear Renal Cell Carcinoma. Preprint.
22.
go back to reference Foo SL, Yap G, Cui J, Lim LHK. Annexin-A1 - A blessing or a curse in Cancer? Trends in molecular medicine. 2019;25:315–27. Foo SL, Yap G, Cui J, Lim LHK. Annexin-A1 - A blessing or a curse in Cancer? Trends in molecular medicine. 2019;25:315–27.
23.
go back to reference Bombelli S, Torsello B, De Marco S, Lucarelli G, Cifola I, Grasselli C, et al. 36-kDa annexin A3 isoform negatively modulates lipid storage in Clear Cell Renal Cell Carcinoma cells. Am J Pathol. 2020;190:2317–26.CrossRefPubMed Bombelli S, Torsello B, De Marco S, Lucarelli G, Cifola I, Grasselli C, et al. 36-kDa annexin A3 isoform negatively modulates lipid storage in Clear Cell Renal Cell Carcinoma cells. Am J Pathol. 2020;190:2317–26.CrossRefPubMed
24.
go back to reference Yu S, Bian H, Gao X, Gui L. Annexin A9 promotes invasion and metastasis of colorectal cancer and predicts poor prognosis. Int J Mol Med. 2018;41:2185–92.PubMed Yu S, Bian H, Gao X, Gui L. Annexin A9 promotes invasion and metastasis of colorectal cancer and predicts poor prognosis. Int J Mol Med. 2018;41:2185–92.PubMed
25.
go back to reference Zhou Y, Qiu C, Wang T, Tao L, Zhang Z, Yao J. High expression of annexin A9 promotes Cell Proliferation and Migration in Gastric Cancer via the TGF-β signaling pathway. J Environ Pathol Toxicol oncology: official organ Int Soc Environ Toxicol Cancer. 2021;40:87–94.CrossRef Zhou Y, Qiu C, Wang T, Tao L, Zhang Z, Yao J. High expression of annexin A9 promotes Cell Proliferation and Migration in Gastric Cancer via the TGF-β signaling pathway. J Environ Pathol Toxicol oncology: official organ Int Soc Environ Toxicol Cancer. 2021;40:87–94.CrossRef
26.
go back to reference Jiang G, Wang P, Wang W, Li W, Dai L, Chen K. Annexin A13 promotes tumor cell invasion in vitro and is associated with metastasis in human colorectal cancer. Oncotarget. 2017;8:21663–73.CrossRefPubMedPubMedCentral Jiang G, Wang P, Wang W, Li W, Dai L, Chen K. Annexin A13 promotes tumor cell invasion in vitro and is associated with metastasis in human colorectal cancer. Oncotarget. 2017;8:21663–73.CrossRefPubMedPubMedCentral
27.
go back to reference Xue GL, Zhang C, Zheng GL, Zhang LJ, Bi JW. Annexin A13 predicts poor prognosis for lung adenocarcinoma patients and accelerates the proliferation and migration of lung adenocarcinoma cells by modulating epithelial-mesenchymal transition. Fundam Clin Pharmacol. 2020;34:687–96.CrossRefPubMed Xue GL, Zhang C, Zheng GL, Zhang LJ, Bi JW. Annexin A13 predicts poor prognosis for lung adenocarcinoma patients and accelerates the proliferation and migration of lung adenocarcinoma cells by modulating epithelial-mesenchymal transition. Fundam Clin Pharmacol. 2020;34:687–96.CrossRefPubMed
28.
29.
go back to reference Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23:74–88.CrossRefPubMed Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23:74–88.CrossRefPubMed
30.
go back to reference Liu J, Peng Y, Wei W. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol. 2022;32:30–44.CrossRefPubMed Liu J, Peng Y, Wei W. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol. 2022;32:30–44.CrossRefPubMed
31.
go back to reference Pelizon C. Down to the origin: Cdc6 protein and the competence to replicate. Trends Cell Biol. 2003;13:110–3.CrossRefPubMed Pelizon C. Down to the origin: Cdc6 protein and the competence to replicate. Trends Cell Biol. 2003;13:110–3.CrossRefPubMed
32.
go back to reference Deng Y, Jiang L, Wang Y, Xi Q, Zhong J, Liu J, et al. High expression of CDC6 is associated with accelerated cell proliferation and poor prognosis of epithelial ovarian cancer. Pathol Res Pract. 2016;212:239–46.CrossRefPubMed Deng Y, Jiang L, Wang Y, Xi Q, Zhong J, Liu J, et al. High expression of CDC6 is associated with accelerated cell proliferation and poor prognosis of epithelial ovarian cancer. Pathol Res Pract. 2016;212:239–46.CrossRefPubMed
33.
go back to reference Youn Y, Lee JC, Kim J, Kim JH, Hwang JH. Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells. Sci Rep. 2020;10:16518.CrossRefPubMedPubMedCentral Youn Y, Lee JC, Kim J, Kim JH, Hwang JH. Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells. Sci Rep. 2020;10:16518.CrossRefPubMedPubMedCentral
34.
go back to reference Jiang W, Yu Y, Liu J, Zhao Q, Wang J, Zhang J, et al. Downregulation of Cdc6 inhibits tumorigenesis of osteosarcoma in vivo and in vitro. Volume 115. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie; 2019. p. 108949. Jiang W, Yu Y, Liu J, Zhao Q, Wang J, Zhang J, et al. Downregulation of Cdc6 inhibits tumorigenesis of osteosarcoma in vivo and in vitro. Volume 115. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie; 2019. p. 108949.
35.
go back to reference Mahadevappa R, Neves H, Yuen SM, Bai Y, McCrudden CM, Yuen HF, et al. The prognostic significance of Cdc6 and Cdt1 in breast cancer. Sci Rep. 2017;7:985.CrossRefPubMedPubMedCentral Mahadevappa R, Neves H, Yuen SM, Bai Y, McCrudden CM, Yuen HF, et al. The prognostic significance of Cdc6 and Cdt1 in breast cancer. Sci Rep. 2017;7:985.CrossRefPubMedPubMedCentral
36.
go back to reference Yicong Y, Wang Y, Denglong W, Baoying H. Increased CDC6 expression associates with poor prognosis in patients with Clear Cell Renal Cell Carcinoma. Front Oncol. 2021;11:666418.CrossRefPubMed Yicong Y, Wang Y, Denglong W, Baoying H. Increased CDC6 expression associates with poor prognosis in patients with Clear Cell Renal Cell Carcinoma. Front Oncol. 2021;11:666418.CrossRefPubMed
Metadata
Title
Potential prognostic and therapeutic value of ANXA8 in renal cell carcinoma: based on the comprehensive analysis of annexins family
Authors
Li-Hui Wang
Bo Cao
Yun-Long Li
Bao-Ping Qiao
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11165-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine